They are Gralise (gabapentin extended release), Qutenza
(capsaicin), Lyrica (pregabalin), Neurontin (gabapentin), and Lidoderm/Versatis (lidocaine).
President and CEO of Acorda, stated, "The acquisition of Qutenza
and NP-1998 enables us to expand into the area of neuropathic pain management.
The agreement closely follows the European Commission's approval received in May 2009, of Qutenza
(capsaicin 179 mg) cutaneous patch for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal pain products.
, Fentora are some of the pipeline candidates in the regulatory filing stage for approval.
FDA approved Qutenza
for the management of postherpetic neuralgia (PHN).
the market is clearly coming to grips with the power of Qutenza
NeurogesX Inc's (NASDAQ: NGSX) Qutenza
, a cutaneous (skin) patch designed to treat peripheral neuropathic pain conditions, has significant market opportunity, in our view.
NeurogesX Obtains FDA Approval for Qutenza
Thursday, 2/9 - The Anesthetic and Analgesic Drug Products Advisory Committee discusses the available efficacy and safety data for a supplemental new drug application for Qutenza
(capsaicin 8%) Patch, by NeurogesX Inc.
Thursday, 2/9 - The Anesthetic and Analgesic Drug Products Advisory Committee discusses the efficacy and safety data for supplemental new drug application for QUTENZA
(capsaicin 8%) Patch by NeurogesX Inc.
Proceeds are expected to be used to further support commercialization activities for Qutenza
(capsaicin) 8% patch, the clinical development of the Company's lead product candidate, NGX-1998, a non-patch topically applied liquid formulation of high-concentration capsaicin, as well as general corporate purposes.
commercial launch of Qutenza
(capsaicin) 8% patch for the management of neuropathic pain associated with postherpetic neuralgia (PHN).